We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Theratechnologies Inc | TSX:TH | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.20 | 8.58% | 2.53 | 2.52 | 2.53 | 2.55 | 2.36 | 2.36 | 43,912 | 15:17:51 |
From Dec 2023 to Dec 2024
By Adriano Marchese
Theratechnologies shares were sharply lower Tuesday morning after the company said U.S. regulators will continue to review its formulation to treat HIV-related weight imbalances.
At 9:37 a.m. ET, shares trading in Toronto were down over 13% at 2.15 Canadian dollars ($1.59).
The biopharmaceutical company said it has received a correspondence from the U.S. Food and Drug Administration stating that it will continue its review of Theratechnologies' supplemental biologics license application for the F8 formulation of tesamorelin.
Tesamorelin is a treatment for HIV-associated lipodystrophy, syndromes that cause fat loss in some parts of the body while gaining it in others.
The FDA told Theratechnologies that it is continuing its review of the application beyond the Prescription Drug User Fee Act.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 23, 2024 10:01 ET (15:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Theratechnologies Chart |
1 Month Theratechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
